People · Operator
Named in public records as an officer, director or promoter · active 2011–2012 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Neos Therapeutics, Inc. | — | Pharmaceuticals | Series B | $163.6M | $701.3M | 2011 |
Mark Van Ausdal at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Van Ausdal on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Clark | 1 | 5 |
| Bryant Fong | 1 | 5 |
| Edward Schnipper | 1 | 4 |
| Victor Miller | 1 | 4 |
| Karl Handelsman | 1 | 3 |
| Bryan Hill | 1 | 3 |
| Alan Heller | 1 | 2 |
| Steven Lutz | 1 | 2 |
| Ralph Iannelli | 1 | 2 |
| Mark Tengler | 1 | 2 |
| Margaret Lokash | 1 | 1 |
| Stacie Switzer | 1 | 1 |
| Richard Eisenstadt | 1 | 1 |
| Asif Mughal | 1 | 1 |
| Vipin Garg | 1 | 1 |
| Dorothy Frank | 1 | 1 |
| Christopher Clement | 1 | 1 |
| Arlen Ewart | 1 | 1 |
| Dorothy Engelking | 1 | 1 |
| Russ McMahen | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.